Latest Expert Opinions

Signal
Opinion
Expert
COMMENT
COMMENT
January 14, 2019
The leading way way to play phosphates and potash in North America. He likes NTR, but because he's a mid-cap manager (and NTR is large cap) he prefers IFOS-X in this space within this cycle.
Show full opinionHide full opinion
Nutrien Ltd. (NTR-T)
January 14, 2019
The leading way way to play phosphates and potash in North America. He likes NTR, but because he's a mid-cap manager (and NTR is large cap) he prefers IFOS-X in this space within this cycle.
BUY
BUY
January 14, 2019
It looks cheap and the balance sheet is not distressed. He likes it here. The risk/reward is good. They have quality crude and get better pricing than its Alberta peers.
Show full opinionHide full opinion
It looks cheap and the balance sheet is not distressed. He likes it here. The risk/reward is good. They have quality crude and get better pricing than its Alberta peers.
BUY
BUY
January 14, 2019
Loves it. One of his biggest holdings. It got hammered, but actually holds net cash and generates $4+/share. Incredibly cheap. They get Brent Oil pricing, another upside. It'll go back to mid-$20's.
Show full opinionHide full opinion
Loves it. One of his biggest holdings. It got hammered, but actually holds net cash and generates $4+/share. Incredibly cheap. They get Brent Oil pricing, another upside. It'll go back to mid-$20's.
SHORT
SHORT
January 14, 2019
Not his favourite cannabis stock. They've diluted shares and are buying another company, which tells him that they're buying with stocks, not cash, which tells him that management believes their company is overvalued. ACB is very high compared to its peers. He's shorting it.
Show full opinionHide full opinion
Aurora Cannabis (ACB-T)
January 14, 2019
Not his favourite cannabis stock. They've diluted shares and are buying another company, which tells him that they're buying with stocks, not cash, which tells him that management believes their company is overvalued. ACB is very high compared to its peers. He's shorting it.
PAST TOP PICK
PAST TOP PICK
January 14, 2019
(A Top Pick Mar 26/18, Up 97%) They smartly bought some spectrum rights a few years ago, and now they're on the fringe of the 5G spectrum. So the value of their spectrum rights will be realized later this year. He took profits, and would be lightening up on this now as the stock does well.
Show full opinionHide full opinion
TeraGo Inc. (TGO-T)
January 14, 2019
(A Top Pick Mar 26/18, Up 97%) They smartly bought some spectrum rights a few years ago, and now they're on the fringe of the 5G spectrum. So the value of their spectrum rights will be realized later this year. He took profits, and would be lightening up on this now as the stock does well.
PAST TOP PICK
PAST TOP PICK
January 14, 2019
(A Top Pick Mar 26/18, Down 30%) Also a top pick, so he'll comment there.
Show full opinionHide full opinion
(A Top Pick Mar 26/18, Down 30%) Also a top pick, so he'll comment there.
PAST TOP PICK
PAST TOP PICK
January 14, 2019
(A Top Pick Mar 26/18, Down 54%) He slightly reduced his position, but still holds it. They got into a business agreement with Sun Pharma, a bigger company, that was distributing one of the biggest drugs. They did a big promotion last year and the stock did very well, but they stopped promoting it. The inventory built up and their orders to Cipher dwindled to almost nothing. CPH stock got punished. They've since solved it with a long-term supply agreement. Also, they have two new drugs approved in 2018 with at least three more in 2019. The founder just bought a bunch of shares, which is a good sign.
Show full opinionHide full opinion
(A Top Pick Mar 26/18, Down 54%) He slightly reduced his position, but still holds it. They got into a business agreement with Sun Pharma, a bigger company, that was distributing one of the biggest drugs. They did a big promotion last year and the stock did very well, but they stopped promoting it. The inventory built up and their orders to Cipher dwindled to almost nothing. CPH stock got punished. They've since solved it with a long-term supply agreement. Also, they have two new drugs approved in 2018 with at least three more in 2019. The founder just bought a bunch of shares, which is a good sign.